Author

Petar Svorcan

UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY
UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Petar Svorcan  et al.

THE POSITIVE EFFECTS OF SYNBIOTICS ON LIVER STEATOSIS BY IMPROVING GUT MICROBIOLOGY- RANDOMIZED CONTROLLED TRIAL
THE POSITIVE EFFECTS OF SYNBIOTICS ON LIVER STEATOSIS BY IMPROVING GUT MICROBIOLOGY- RANDOMIZED CONTROLLED TRIAL

Petar Svorcan  et al.

H.PYLORI INFECTION AND NUTRITIONAL STATUS IN END-STAGE RENAL DISEASE PATIENTS
H.PYLORI INFECTION AND NUTRITIONAL STATUS IN END-STAGE RENAL DISEASE PATIENTS

Petar Svorcan  et al.

THE IMPORTANCE OF GUT TRANSITION TIME AND GUT MICROBIOME COMPOSITION IN NON-ALCOHOLIC FATTY LIVER DISEASE DEVELOPMENT
THE IMPORTANCE OF GUT TRANSITION TIME AND GUT MICROBIOME COMPOSITION IN NON-ALCOHOLIC FATTY LIVER DISEASE DEVELOPMENT

Petar Svorcan  et al.

Item 1 - 4 / 4
1